Why the study?
The study was conducted to evaluate the efficacy and safety of rivaroxaban versus low molecular weight heparin for preventing deep vein thrombosis after hip arthroplasty.
Does rivaroxaban prevent deep vein thrombosis compared to low molecular weight heparin in patients after primary unilateral hip arthroplasty?
Does rivaroxaban prevent deep vein thrombosis compared to low molecular weight heparin in patients after primary unilateral hip arthroplasty?
Rivaroxaban 10 mg/d for 5 weeks is effective and safe for preventing deep vein thrombosis after primary unilateral hip arthroplasty.
Supports rivaroxaban over LMWH for DVT prophylaxis after hip arthroplasty; confirms efficacy and safety in this RCT.
To evaluate the efficacy and safety of rivaroxaban versus low molecular weight heparin for the prevention of deep vein thrombosis after hip arthroplasty, 30 patients with primary unilateral hip arthroplasty in the Yijishan Hospital of Wannan Medical College between January 2017 and December 2018 were selected and randomly divided into the rivaroxaban group and the low molecular weight heparin group. Treatments started 6 h after replacement, the patients in the rivaroxaban group received rivaroxaban 10 mg/d for 5 w and the another group received low molecular weight heparin 4100 U/d for 2 w. Results indicated that full course of rivaroxaban demonstrated distinct efficacy with safety in preventing deep vein thrombosis after hip arthroplasty.
No takes yet. Share an insight, caveat, or question.
Liyun Dang (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: